Emerging roles of ATG7 in human health and disease

Show full item record



Permalink

http://hdl.handle.net/10138/340543

Citation

Collier , J J , Suomi , F , Olahova , M , McWilliams , T G & Taylor , R W 2021 , ' Emerging roles of ATG7 in human health and disease ' , EMBO molecular medicine , vol. 13 , no. 12 , 14824 . https://doi.org/10.15252/emmm.202114824

Title: Emerging roles of ATG7 in human health and disease
Author: Collier, Jack J.; Suomi, Fumi; Olahova, Monika; McWilliams, Thomas G.; Taylor, Robert W.
Contributor organization: STEMM - Stem Cells and Metabolism Research Program
Department of Anatomy
Date: 2021-12-07
Language: eng
Number of pages: 20
Belongs to series: EMBO molecular medicine
ISSN: 1757-4676
DOI: https://doi.org/10.15252/emmm.202114824
URI: http://hdl.handle.net/10138/340543
Abstract: The cardinal stages of macroautophagy are driven by core autophagy-related (ATG) proteins, whose ablation largely abolishes intracellular turnover. Disrupting ATG genes is paradigmatic of studying autophagy deficiency, yet emerging data suggest that ATG proteins have extensive biological importance beyond autophagic elimination. An important example is ATG7, an essential autophagy effector enzyme that in concert with other ATG proteins, also regulates immunity, cell death and protein secretion, and independently regulates the cell cycle and apoptosis. Recently, a direct association between ATG7 dysfunction and disease was established in patients with biallelic ATG7 variants and childhood-onset neuropathology. Moreover, a prodigious body of evidence supports a role for ATG7 in protecting against complex disease states in model organisms, although how dysfunctional ATG7 contributes to manifestation of these diseases, including cancer, neurodegeneration and infection, in humans remains unclear. Here, we systematically review the biological functions of ATG7, discussing the impact of its impairment on signalling pathways and human pathology. Future studies illuminating the molecular relationship between ATG7 dysfunction and disease will expedite therapies for disorders involving ATG7 deficiency and/or impaired autophagy.
Subject: ATG7
autophagy
disease
neurodegeneration
therapeutics
5-HT6 RECEPTOR ANTAGONIST
PROTEIN-ACTIVATING ENZYME
LIFE-SPAN EXTENSION
BETA-CELL MASS
LC3-ASSOCIATED PHAGOCYTOSIS
AUTOPHAGY DEFICIENCY
STRUCTURAL INSIGHTS
REQUIRE AUTOPHAGY
BINDING PROTEIN
PANETH CELLS
3111 Biomedicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
EMBO_Mol_Med_20 ... man_health_and_disease.pdf 1.816Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record